Suresh L Mehta, TaeHee Kim, Bharath Chelluboina, Raghu Vemuganti
{"title":"Tau and GSK-3β are Critical Contributors to α-Synuclein-Mediated Post-Stroke Brain Damage.","authors":"Suresh L Mehta, TaeHee Kim, Bharath Chelluboina, Raghu Vemuganti","doi":"10.1007/s12017-022-08731-0","DOIUrl":null,"url":null,"abstract":"<p><p>Post-stroke secondary brain damage is significantly influenced by the induction and accumulation of α-Synuclein (α-Syn). α-Syn-positive inclusions are often present in tauopathies and elevated tau levels and phosphorylation promotes neurodegeneration. Glycogen synthase kinase 3β (GSK-3β) is a known promoter of tau phosphorylation. We currently evaluated the interaction of α-Syn with GSK-3β and tau in post-ischemic mouse brain. Transient focal ischemia led to increased cerebral protein-protein interaction of α-Syn with both GSK-3β and tau and elevated tau phosphorylation. Treatment with a GSK-3β inhibitor prevented post-ischemic tau phosphorylation. Furthermore, α-Syn interaction was observed to be crucial for post-ischemic GSK-3β-dependent tau hyperphosphorylation as it was not seen in α-Syn knockout mice. Moreover, tau knockout mice show significantly smaller brain damage after transient focal ischemia. Overall, the present study indicates that GSK-3β catalyzes the α-Syn-dependent tau phosphorylation and preventing this interaction is crucial to limit post-ischemic secondary brain damage.</p>","PeriodicalId":19304,"journal":{"name":"NeuroMolecular Medicine","volume":"25 1","pages":"94-101"},"PeriodicalIF":3.9000,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249510/pdf/nihms-1895702.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroMolecular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12017-022-08731-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/11/30 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Post-stroke secondary brain damage is significantly influenced by the induction and accumulation of α-Synuclein (α-Syn). α-Syn-positive inclusions are often present in tauopathies and elevated tau levels and phosphorylation promotes neurodegeneration. Glycogen synthase kinase 3β (GSK-3β) is a known promoter of tau phosphorylation. We currently evaluated the interaction of α-Syn with GSK-3β and tau in post-ischemic mouse brain. Transient focal ischemia led to increased cerebral protein-protein interaction of α-Syn with both GSK-3β and tau and elevated tau phosphorylation. Treatment with a GSK-3β inhibitor prevented post-ischemic tau phosphorylation. Furthermore, α-Syn interaction was observed to be crucial for post-ischemic GSK-3β-dependent tau hyperphosphorylation as it was not seen in α-Syn knockout mice. Moreover, tau knockout mice show significantly smaller brain damage after transient focal ischemia. Overall, the present study indicates that GSK-3β catalyzes the α-Syn-dependent tau phosphorylation and preventing this interaction is crucial to limit post-ischemic secondary brain damage.
脑卒中后继发性脑损伤在很大程度上受到α-突触核蛋白(α-Syn)的诱导和积累的影响。α-Syn阳性内含物经常出现在tau病中,tau水平的升高和磷酸化促进了神经退行性变。糖原合成酶激酶 3β(GSK-3β)是一种已知的 tau 磷酸化促进因子。我们目前评估了缺血后小鼠大脑中α-Syn与GSK-3β和tau的相互作用。短暂的局灶性缺血导致α-Syn与GSK-3β和tau的脑蛋白-蛋白相互作用增加,tau磷酸化升高。使用 GSK-3β 抑制剂可防止缺血后 tau 的磷酸化。此外,还观察到α-Syn相互作用对缺血后依赖于GSK-3β的tau过度磷酸化至关重要,因为在α-Syn基因敲除小鼠中看不到这种作用。此外,tau基因敲除小鼠在短暂局灶性缺血后的脑损伤明显较小。总之,本研究表明,GSK-3β催化了α-Syn依赖的tau磷酸化,而防止这种相互作用对限制缺血后继发性脑损伤至关重要。
期刊介绍:
NeuroMolecular Medicine publishes cutting-edge original research articles and critical reviews on the molecular and biochemical basis of neurological disorders. Studies range from genetic analyses of human populations to animal and cell culture models of neurological disorders. Emerging findings concerning the identification of genetic aberrancies and their pathogenic mechanisms at the molecular and cellular levels will be included. Also covered are experimental analyses of molecular cascades involved in the development and adult plasticity of the nervous system, in neurological dysfunction, and in neuronal degeneration and repair. NeuroMolecular Medicine encompasses basic research in the fields of molecular genetics, signal transduction, plasticity, and cell death. The information published in NEMM will provide a window into the future of molecular medicine for the nervous system.